Departamento de Gastroenterologia, Divisao de Gastroenterologia e Hepatologia Clinica, Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.
Instituto do Cancer do Estado de Sao Paulo (ICESP), Hospital das Clinicas (HCFMUSP), Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR.
Clinics (Sao Paulo). 2020 Oct 26;75:e2192. doi: 10.6061/clinics/2020/e2192. eCollection 2020.
More than 18 million people in 188 countries have been diagnosed as having coronavirus disease (COVID-19), and COVID-19 has been responsible for more than 600,000 deaths worldwide. Brazil is now the second most affected country globally. Faced with this scenario, various public health measures and changes in the daily routines of hospitals were implemented to stop the pandemic. Patients with hepatocellular carcinoma (HCC) are at an increased risk for severe COVID-19 as they present with two major diseases: cancer and concomitant chronic liver disease. The COVID-19 pandemic can significantly impact the management of HCC patients from diagnosis to treatment strategies. These patients need special attention and assistance at this time, especially since treatment for tumors cannot be delayed in most cases. The aim of this guideline was to standardize the management of HCC patients during the COVID-19 pandemic. This document was developed, on the basis of the best evidence available, by a multidisciplinary team from Instituto do Câncer do Estado de São Paulo (ICESP), and Instituto Central of the Hospital das Clínicas da Universidade de São Paulo (HC-FMUSP), which are members of the São Paulo Clínicas Liver Cancer Group.
全球 188 个国家和地区超过 1800 万人被诊断感染了冠状病毒病（COVID-19），COVID-19 已导致全球超过 60 万人死亡。巴西目前是全球受影响第二严重的国家。面对这种情况，为了阻止大流行，实施了各种公共卫生措施和改变医院的日常工作。患有肝细胞癌（HCC）的患者患严重 COVID-19 的风险增加，因为他们患有两种主要疾病：癌症和同时存在的慢性肝病。COVID-19 大流行可能会严重影响 HCC 患者从诊断到治疗策略的管理。这些患者此时需要特别关注和帮助，特别是因为在大多数情况下，肿瘤的治疗不能延迟。本指南旨在为 COVID-19 大流行期间 HCC 患者的管理制定标准。本文件是由来自 São Paulo Clínicas Liver Cancer Group 的 São Paulo 的 Instituto do Câncer do Estado de São Paulo (ICESP) 和 Instituto Central do Hospital das Clínicas da Universidade de São Paulo (HC-FMUSP) 的多学科团队在现有最佳证据的基础上制定的。
